Myocet, a liposomal formulation of doxorubicin, offers a significantly improved therapeutic index with less cardiotoxicity and equal efficacy compared to conventional doxorubicin in breast cancer.
Does liposome-encapsulated doxorubicin citrate reduce cardiotoxicity compared to conventional doxorubicin in patients with metastatic breast cancer?
Liposome-encapsulated doxorubicin provides an equally efficacious but less cardiotoxic alternative to conventional doxorubicin, reducing the risk of congestive heart failure in breast cancer therapy.
Doxorubicin, either as a single agent or in combination regimens, is considered to be one of the most active chemotherapeutic agents in the treatment of metastatic breast cancer. However, its clinical utility is limited by a cumulative, dose-dependent cardiac myopathy that can lead to potentially fatal congestive heart failure. Considerable research has gone into improving the therapeutic index of doxorubicin-based regimens. A new liposomal formulation of doxorubicin (Myocet, Elan Pharmaceuticals) has a significantly improved therapeutic index compared with conventional doxorubicin. The development of Myocet, a less cardiotoxic, better tolerated and equally efficacious doxorubicin, extends the therapeutic options in the overall management of breast cancer.
Batist et al. (Sun,) conducted a review in metastatic breast cancer. Myocet (liposomal formulation of doxorubicin) vs. conventional doxorubicin was evaluated. Myocet, a liposomal formulation of doxorubicin, offers a significantly improved therapeutic index with less cardiotoxicity and equal efficacy compared to conventional doxorubicin in breast cancer.